



**Information to the Copenhagen Stock Exchange no. 2/2006
Humlebæk, 8 February 2006**

**New segmentation and changes in accounting
policies applied**

Segmentation

Following the restructuring announced at the publication of Coloplast's strategy towards 2012, we have adjusted our financial reporting to the new organisation with effect from the first quarter of 2005/06. The restructuring consolidated the business areas skin health and wound care into one business area, which will in future be included in a global matrix organisation together with the ostomy care and continence care business areas.

The business areas remain the primary segmentation and the geographical markets, Europe, The Americas and Rest of the world, remain the secondary segmentation.

These organisational changes prompt the following changes in financial reporting:

- The gross revenue figures for Coloplast's products are reported quarterly for each of the four business areas while, in the past, they were only stated in the annual report.
- An aggregated revenue figure is reported for all business areas in the group while, in the past, revenue figures were stated separately for the ostomy care and continence care business areas and home care (chronic care) and for the wound care, skin health and breast care business areas (SBU). Non-allocated costs and eliminations are still reported separately.
- An aggregated operating profit figure is reported for all business areas in the group while, in the past, operating profit figures were stated separately for the ostomy care and continence care business areas and home care (chronic care) and for the wound care, skin health and breast care business areas (SBU). Non-allocated costs and eliminations are still separately.

The breast care business area remains an independent business unit, but since the revenue, profit and net assets of this business unit account for less than 10% of the Group's corresponding key figures, the financial result for the area will in future be included in the overall reporting under chronic care.

Accounting policies applied

With effect from the financial year 2005/06 Coloplast implemented IFRS 2, which standards have been approved for use in the European Union. In accordance with these accounting standards, share-based compensation is measured at fair value.

In the case of cash-settled, share-based payment arrangements, the fair value of options earned during the period is recognised as a staff cost, while the adjustment for fair value of options earned in previous periods is recognised as a financial item.

For equity-settled, share-based payment arrangements, the fair value of options is determined at the time of allocation. The option value is then recognised over the earnings period as a staff cost.

Option schemes allocated before 30 September 2005 are considered cash-settled arrangements.

For your information, we have attached quarterly comparison figures for 2004/05 for the new primary segment as well quarterly income statement and balance sheet for 2004/05 adjusted for the new accounting policies. The attachments can be downloaded in Excel format from Coloplasts homepage.

Lene Skole
Group director, CFO

This announcement is available in a Danish and an English version. In case of doubt the Danish version shall prevail.

For further information: Group director, CFO Lene Skole, phone + 45 4911 1665 or IR manager Jørgen Fischer Ravn, phone + 45 4911 1308

1. Segment information per quarter (unaudited)

Primary segment - business activities				
Group, 2004/05				
<i>mDKK</i>	Q1	Q2	Q3	Q4
Revenue				
Chronic care + Breast care	1.565	1.534	1.687	1.742
Not allocated costs and eliminations	0	0	0	0
Revenue total	1.565	1.534	1.687	1.742
Operating profit				
Chronic care + Breast care	244	305	325	385
Not allocated costs and eliminations	-64	-76	-61	-64
Operating profit total	180	229	264	321

Additional information - gross revenue Coloplast products

Group, 2004/05				
<i>mDKK</i>	Q1	Q2	Q3	Q4
Gross revenue per business area for Coloplast products				
Ostomy care	647	614	686	709
Continence care	389	380	414	433
Wound & Skin care	264	271	294	308
Breast care	95	114	139	123

Restatement of comparison figures per quarter 2004/05
Coloplast group

	Q1, 2004/05			Acc. Q2, 2004/05			Acc. Q3, 2004/05			Acc. Q4, 2004/05									
	As reported	Share options	After adjustment	As reported	Share options	After adjustment	As reported	Share options	After adjustment	As reported	Share options	After adjustment							
Revenue	1.565			3.099			3.099			4.786			6.528			4.786			6.528
Cost of sales	-677			-1.274			-1.275			-1.947			-1.948			-2.601			-2.603
Gross profit	888	0	888	1.825	-1	1.824	2.839	-1	2.838	2.839	-1	2.838	3.927	-2	3.925	3.927	-2	3.925	3.925
Distribution costs	-482			-947			-948			-1.434			-1.435			-1.943			-1.945
Administrative expenses	-179			-180			-354			-560			-564			-738			-744
Research and development costs	-56			-56			-106			-160			-161			-214			-215
Other operating income	13			13			15			19			19			15			15
Other operating expenses	-2			-2			-5			-5			-5			-16			-16
Separate items	0			0			-17			-19			-19			-26			-26
Operating profit	182	-2	180	413	-4	409	680	-7	673	680	-7	673	1.005	-11	994	1.005	-11	994	994
Income from investments in associates before tax	0			0			0			0			0			0			0
Financial income	32			32			19			30			30			48			48
Financial expenses	-62			-66			-71			-73			-103			-168			-212
Profit before tax	152	-6	146	361	-6	355	607	-40	567	607	-40	567	885	-55	830	885	-55	830	830
Tax on profit for the year	-53			-51			-119			-192			-290			15			-275
Net profit for the year	99	-4	95	242	-4	238	415	-29	386	415	-29	386	595	-40	555	595	-40	555	555
Minority interests	-1			-2			-2			-1			-2			-2			-2
Coloplast's share of profit for the year	98	-4	94	240	-4	236	414	-29	385	414	-29	385	593	-40	553	593	-40	553	553
Acquired patents and trademarks	13			13			12			11			17			17			17
Goodwill	298			298			298			302			302			327			327
Software	112			112			119			121			147			147			147
Prepayment for intangible assets and intangible assets in progress	8			8			7			16			5			5			5
Intangible assets	431	0	431	436	0	436	450	0	450	450	0	450	496	0	496	496	0	496	496
Land and buildings	1.128			1.128			1.133			1.125			1.125			1.127			1.127
Plant and machinery	409			409			437			461			569			569			569
Other fixtures and fittings, tools and equipment	217			217			227			221			211			211			211
Prepayments and property, plant and equipment in progress	311			311			292			300			181			181			181
Property, plant and equipment	2.065	0	2.065	2.089	0	2.089	2.107	0	2.107	2.107	0	2.107	2.088	0	2.088	2.088	0	2.088	2.088
Investments in associates	2			2			2			1			2			2			2
Other investments	0			0			6			7			6			6			6
Deferred tax asset	94			107			96			100			121			136			160
Investments	96	13	109	104	13	117	108	21	129	108	21	129	144	24	168	144	24	168	168
Fixed assets	2.592	13	2.605	2.629	13	2.642	2.665	21	2.686	2.665	21	2.686	2.728	24	2.752	2.728	24	2.752	2.752
Inventories	825		825	816		816	816		794	816		794	698		698	698		698	698
Trade receivables	1.139			1.139			1.127			1.234			1.224			1.224			1.224
Receivables from associates	6			6			7			7			6			6			6
Other receivables	113			113			103			108			99			99			99
Prepayments	58			58			48			46			37			37			37
Receivables	1.316	0	1.316	1.285	0	1.285	1.395	0	1.395	1.395	0	1.395	1.366	0	1.366	1.366	0	1.366	1.366
Marketable securities	77		77	97		97	142		142	142		142	334		334	334		334	334
Cash and bank balances	723		723	817		817	817		926	817		926	765		765	765		765	765
Current assets	2.941	0	2.941	3.015	0	3.015	3.257	0	3.257	3.257	0	3.257	3.163	0	3.163	3.163	0	3.163	3.163
Assets	5.533	13	5.546	5.644	13	5.657	5.922	21	5.943	5.922	21	5.943	5.891	24	5.915	5.891	24	5.915	5.915
Contributed capital	240			240			240			240			240			240			240
Reserve for exchange rate adjustments							0						3			3			3
Fair value reserve	-58			-58			-87			-100			-109			-109			-109
Proposed dividend for the year	0			0			0			0			162			162			162
Retained earnings	2.107			2.075			2.255			2.375			2.276			2.276			2.276
Equity	2.289	-32	2.257	2.408	-31	2.377	2.515	-52	2.463	2.515	-52	2.463	2.572	-60	2.512	2.572	-60	2.512	2.512
Minority interests	4		4	3		3	3		1	3		1	2		2	2		2	2
Provision for pensions and similar liabilities	83			83			79			81			80			80			80
Provision for deferred tax	17			17			31			26			61			61			61
Other provisions	11			11			10			10			14			14			14
Provisions	111	0	111	120	0	120	117	0	117	117	0	117	155	0	155	155	0	155	155
Mortgage debt	523			523			522			488			489			489			489
Other credit institutions	1.188			1.188			1.202			1.297			1.297			1.297			1.297
Other payables	0			0			27			0			0			0			0
Deferred income	305			305			255			172			167			167			167
Non-current liabilities	2.016	26	2.042	1.979	27	2.006	1.957	47	2.004	1.957	47	2.004	1.893	57	1.950	1.893	57	1.950	1.950
Mortgage debt	5			5			5			5			5			5			5
Other credit institutions	228			228			174			194			67			67			67
Trade payables	248			248			245			284			300			300			300
Income tax	92			91			34			82			130			130			130
Other payables	532			552			546			623			603			603			603
Deferred income	8			8			130			144			164			164			164
Current liabilities	1.113	19	1.132	1.134	17	1.151	1.332	26	1.358	1.332	26	1.358	1.269	27	1.296	1.269	27	1.296	1.296
Current and Non-current liabilities	3.129	45	3.174	3.113	44	3.157	3.289	73	3.362	3.289	73	3.362	3.162	84	3.246	3.162	84	3.246	3.246
Equity and liabilities	5.533	13	5.546	5.644	13	5.657	5.922	21	5.943	5.922	21	5.943	5.891	24	5.915	5.891	24	5.915	5.915